Shots:
- Biomica (Evogene’s subsidiary) & Shanghai Lishan Biopharmaceuticals have entered into an exclusive worldwide licensing agreement for BMC128, currently in P-I trial
- As per the deal, Lishan Biotech will receive exclusive rights to develop, manufacture, & commercialize BMC128, with Biomica receiving development milestone payments & royalties on future commercial sales
- Lishan Biotech is planning to advance BMC128 into a P-II trial while pursuing regulatory filings in China & the US to support its future commercialization
Ref: Globenewswire | Image: Evogene & Lishan Biotech | Press Release
Related News: PrimeGen US to Go Public via DT Cloud Star Acquisition Corporation’s SPAC Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
